The Medicines Company’s Curacyte Acquisition Points To A Post-Angiomax Future
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal expands TMC’s pipeline, with an eye on the antifibrinolytic market left empty by the Trasylol withdrawal.